The US decision to launch a Section 301 trade investigation into Germany’s pharmaceutical pricing has pushed drug policy into the spotlight, with potential implications for tariffs, market access and future drug launches in Europe. For US pharmaceutical stocks, the issue is not just legal; it is about where future cash flows may be at risk or better protected. This article looks at three large US pharmaceutical stocks that appear closely exposed to this news, helping you think through where the current headlines might support an investment case and where they could argue for more caution.

Insmed (INSM)

Overview: Insmed is a US biotech company focused on therapies for serious and rare diseases, with an approved drug, ARIKAYCE, for certain complex lung infections and a pipeline that includes late stage treatments for bronchiectasis, pulmonary hypertension and several gene therapy programs. Its portfolio targets patients with limited existing options across the US, Europe, Japan and other international markets.

Operations: Insmed generates about US$819.6m in revenue from developing and commercializing therapies for patients with rare diseases, with roughly US$658.7m from the United States and US$160.8m from international markets.

Market Cap: US$20.8b

Insmed gives you targeted exposure to rare disease drugs at the point where clinical momentum, pricing politics and execution risk all intersect. The company is pushing ahead with brensocatib and treprostinil palmitil in late stage trials, while working through complex questions around how much European governments will pay and how US tariff policy might treat drugs whose intellectual property sits onshore. Management talks openly about pausing certain European launches if pricing feeds back into US reference rules, and the stock still carries high funding and profitability risk alongside ambitious analyst expectations. For investors willing to weigh those trade offs, there is more to Insmed’s story than the headline numbers suggest.

Insmed’s rare disease momentum and trade-sensitive pricing story are only half the picture; the real question is how its cash flows and funding risks stack up in the analysis report for Insmed

Viatris (VTRS)

Overview: Viatris is a global healthcare company that sells branded medicines, generics, complex generics and biosimilars across a wide range of conditions, from cardiovascular disease and diabetes to oncology and respiratory care. Its portfolio spans well known brands like Lyrica, Lipitor, Celebrex, Viagra, EpiPen and others, reaching patients in more than 160 countries.

Operations: Viatris generates about US$17.6b in revenue across four segments, with around US$8.7b from Developed Markets, US$2.5b from Greater China, US$2.2b from Emerging Markets and US$1.2b from the JANZ region.

Market Cap: US$17.9b

Viatris stands out in the US Pharmaceutical Stocks screener because it couples a broad, globally diversified drug portfolio with value signals that suggest the market may be underestimating its cash flow potential. The company is working to shift its mix toward higher margin complex generics, biosimilars and new products like fast acting meloxicam, while still paying a dividend. This introduces both income appeal and payout risk given its recent losses. Management is vocal about tariff and pricing pressures but has a dense global manufacturing footprint and is actively planning mitigation, which matters as the Section 301 investigation keeps European pricing in flux. For investors, the real interest lies in how these moving parts show up in the detailed forecasts, risk scores and cash flow estimates that sit behind the headlines.

Viatris appears to be a cash flow story that the market has not fully priced in, with its global portfolio, dividend, and tariff noise all intersecting. Get the full picture in the analysis report for Viatris

BioMarin Pharmaceutical (BMRN)

Overview: BioMarin Pharmaceutical focuses on developing and selling treatments for rare genetic and metabolic diseases, offering drugs like VOXZOGO for achondroplasia, VIMIZIM and NAGLAZYME for mucopolysaccharidoses, and PALYNZIQ for phenylketonuria to patients worldwide through hospitals, specialty pharmacies and government agencies.

Operations: BioMarin generates about US$3.2b from developing and commercializing its rare disease therapies, with roughly US$1.1b from the United States and about US$2.1b from international markets including Europe, Latin America and the Rest of World.

Market Cap: US$10.6b

BioMarin Pharmaceutical sits at the center of two themes investors are watching closely right now: high value rare disease drugs and global pricing politics. The company relies heavily on premium therapies like VOXZOGO. Recent hypochondroplasia data and a planned 2026 filing could influence how investors view its long term earnings power, while programs such as BMN 401 highlight that not every pipeline bet pays off. At the same time, around two thirds of sales come from outside the US, with management emphasizing that its California based manufacturing and net exporter status may soften some tariff and Section 301 risks tied to Europe. For investors, the key question is how that global rare disease footprint aligns with pricing pressure, a rich P/E multiple and a balance sheet leaning on debt.

BioMarin Pharmaceutical’s premium rare disease portfolio and debt heavy balance sheet raise big questions about future earnings quality. Get the context that ties this together in the analyst forecasts for BioMarin Pharmaceutical

The three US pharmaceutical stocks covered here are only a starting point, and the full US Pharmaceutical Stocks screener surfaces 39 more companies with equally compelling stories around size, health scores and future potential. Use Simply Wall St to identify, analyze and filter the exact catalysts, trade sensitivities and rare disease or global exposure narratives that fit your highest conviction ideas.

Take Control of Your Investment Journey

If Viatris or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others Notice?

Markets move fast, and the next breakout group of stocks often moves before most investors react. Filter fresh, under-the-radar ideas now so you are prepared to respond.

• Spot potential early movers with strong balance sheets by scanning the curated list of solid balance sheet and fundamentals (48 results), which highlights companies investors may overlook while their fundamentals remain a key focus.
• Follow structural themes in automation by tracking companies inside the hand picked 31 robotics and automation stocks, where business developments could gain momentum before they are widely discussed.
• Review the focused 34 power grid technology and infrastructure stocks to analyze businesses that may be exposed to changes in grid spending while prices are still adjusting.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.